… in-licensing of a third integrase inhibitor from Shionogi, we will continue …

… found that switching to an integrase inhibitor was independently associated with … rate of weight gain between integrase inhibitors. Demographic factors or baseline … might be an interaction with integrase inhibitors – especially dolutegravir – needs further …

… of protease inhibitors, or the integrase inhibitor elvitegravir. Others have found that … whether people were taking an integrase inhibitor or not. One question yet …

… start their first treatment. Background Integrase inhibitors are still a relatively recent … differences in weight gain between integrase inhibitors, with more weight gain on … weight gained on some other integrase inhibitors indicate that return to health …

… antiretroviral treatment that contains an integrase inhibitor or tenofovir alafenamide (TAF), … of participants were taking an integrase inhibitor, 40% a boosted protease … participants taking TAF or an integrase inhibitor developed steatosis more quickly or …

… anti-HIV medications, including integrase inhibitors, are associated with greater … regimen. Treatment guidelines recommend integrase inhibitors for first-line antiretroviral therapy … switch differed between specific integrase inhibitors and was present for …

… weight after switching to an integrase inhibitor are not gaining a disproportionate … HIV treatment, especially with an integrase inhibitor. Greater weight gain has been … treatment who switched to an integrase inhibitor with people who never switched …

… antiretroviral regimens containing an integrase inhibitor gain weight after starting … interpretations of these findings credited integrase inhibitors – especially dolutegravir – with … effect. The medications that integrase inhibitors are taken with also …

… out to investigate whether HIV integrase inhibitor drugs also inhibit folate transporters … of dolutegravir and four other integrase inhibitor drugs, together with positive … dolutegravir and the other HIV integrase inhibitors had on folate transporter activity …